{
  "patent_number": "US 12735424",
  "country": "US",
  "title": "New Chemicals That Block Specific Adenosine Receptors for Treating Diseases",
  "original_title": "Fused pyrazine derivatives as A2A / A2B inhibitors",
  "summary": "This patent describes new chemical compounds, called fused pyrazine derivatives, designed to block specific adenosine receptors (A2A and A2B) in the body, which could help treat conditions like cancer, inflammatory, cardiovascular, and neurodegenerative diseases.",
  "what_it_does": "This patent application introduces a group of new chemical compounds, referred to as \"compounds of Formula (I),\" or their \"pharmaceutically acceptable salts.\" These compounds are designed to change how adenosine receptors, specifically the A2A and A2B subtypes, work in the body. By blocking or reducing the activity of these receptors, the compounds aim to be useful in treating various diseases. For example, they could potentially be used to treat certain types of cancer, reduce inflammation, manage cardiovascular problems, or address neurodegenerative conditions.",
  "what_it_does_not_cover": [
    "Does not cover chemical compounds that are not 'fused pyrazine derivatives' or do not fit the specific 'Formula (I)' structure.",
    "Does not cover compounds that activate A2A or A2B receptors, as the focus is on 'inhibitors' or 'modulators' for treatment.",
    "Does not cover compounds that exclusively target other adenosine receptor subtypes like A1 or A3, or entirely different types of receptors.",
    "Does not cover methods of diagnosing diseases using these compounds, only their use in the 'treatment of diseases'.",
    "Does not cover the treatment of diseases that are not related to the activity of adenosine receptors."
  ],
  "filed": "2024-03-28",
  "granted": "2026-09-15",
  "expires": null,
  "status": "active",
  "holder": null,
  "holder_url": null,
  "inventors": [],
  "times_cited": 0,
  "tags": [
    "pharmaceutical",
    "biotech",
    "cancer",
    "inflammatory_diseases",
    "cardiovascular",
    "neurodegenerative_diseases"
  ],
  "abstract": "This application relates to compounds of Formula (I): \n                         \nor pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.",
  "url": "https://patentbrief.org/patent/us/12735424/fused-pyrazine-derivatives-as-a2a-a2b-inhibitors",
  "markdown_url": "https://patentbrief.org/patent/us/12735424/fused-pyrazine-derivatives-as-a2a-a2b-inhibitors/md",
  "google_patents_url": "https://patents.google.com/patent/US12735424",
  "relatedPatents": []
}